115 related articles for article (PubMed ID: 34773915)
1. Prognostic implication of desmoplastic stroma in synovial sarcoma: A histological review.
Toda Y; Yamada Y; Kohashi K; Ishihara S; Ito Y; Susuki Y; Kawaguchi K; Kinoshita I; Kiyozawa D; Mori T; Kuboyama Y; Tateishi Y; Yamamoto H; Fujiwara T; Setsu N; Endo M; Matsumoto Y; Nakashima Y; Mawatari M; Oda Y
Pathol Res Pract; 2021 Dec; 228():153668. PubMed ID: 34773915
[TBL] [Abstract][Full Text] [Related]
2. Histology and grading are important prognostic factors in synovial sarcoma.
Bianchi G; Sambri A; Righi A; Dei Tos AP; Picci P; Donati D
Eur J Surg Oncol; 2017 Sep; 43(9):1733-1739. PubMed ID: 28579008
[TBL] [Abstract][Full Text] [Related]
3. Release of circulating tumor cells and cell-free nucleic acids is an infrequent event in synovial sarcoma: liquid biopsy analysis of 15 patients diagnosed with synovial sarcoma.
Mihály D; Nagy N; Papp G; Pápai Z; Sápi Z
Diagn Pathol; 2018 Oct; 13(1):81. PubMed ID: 30326929
[TBL] [Abstract][Full Text] [Related]
4. When used together SS18-SSX fusion-specific and SSX C-terminus immunohistochemistry are highly specific and sensitive for the diagnosis of synovial sarcoma and can replace FISH or molecular testing in most cases.
Zaborowski M; Vargas AC; Pulvers J; Clarkson A; de Guzman D; Sioson L; Maclean F; Chou A; Gill AJ
Histopathology; 2020 Oct; 77(4):588-600. PubMed ID: 32559341
[TBL] [Abstract][Full Text] [Related]
5. [Roles of immunohistochemistry and detection of SYT-SSX fusion gene in diagnosis of synovial sarcoma].
Sun Y; Sun BC; Zhao XL; Wang J; Chen J; Li XQ; Feng YM; Fang ZW; Hao XS
Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):480-4. PubMed ID: 17845763
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of expression of cancer stem cell markers and fusion gene in synovial sarcoma: Insights into histogenesis and pathogenesis.
Zhou Y; Chen D; Qi Y; Liu R; Li S; Zou H; Lan J; Ju X; Jiang J; Liang W; Shen Y; Pang L; Li F
Oncol Rep; 2017 Jun; 37(6):3351-3360. PubMed ID: 28498445
[TBL] [Abstract][Full Text] [Related]
7. Prognostic implication of SYT-SSX fusion type and clinicopathological parameters for tumor-related death, recurrence, and metastasis in synovial sarcoma.
Sun Y; Sun B; Wang J; Cai W; Zhao X; Zhang S; Hao X
Cancer Sci; 2009 Jun; 100(6):1018-25. PubMed ID: 19385976
[TBL] [Abstract][Full Text] [Related]
8. Establishment and characterization of NCC-SS4-C1: a novel patient-derived cell line of synovial sarcoma.
Tsuchiya R; Yoshimatsu Y; Noguchi R; Ono T; Sei A; Takeshita F; Sugaya J; Iwata S; Yoshida A; Ohtori S; Kawai A; Kondo T
Hum Cell; 2021 May; 34(3):998-1007. PubMed ID: 33611700
[TBL] [Abstract][Full Text] [Related]
9. The prognostic impact of SYT-SSX fusion type and histological grade in pediatric patients with synovial sarcoma treated according to the CWS (Cooperative Weichteilsarkom Studie) trials.
Stegmaier S; Leuschner I; Poremba C; Ladenstein R; Kazanowska B; Ljungman G; Scheer M; Blank B; Bielack S; Klingebiel T; Koscielniak E
Pediatr Blood Cancer; 2017 Jan; 64(1):89-95. PubMed ID: 27621063
[TBL] [Abstract][Full Text] [Related]
10. Prognostic implication of SYT-SSX fusion type in synovial sarcoma: a multi-institutional retrospective analysis in Japan.
Takenaka S; Ueda T; Naka N; Araki N; Hashimoto N; Myoui A; Ozaki T; Nakayama T; Toguchida J; Tanaka K; Iwamoto Y; Matsumine A; Uchida A; Ieguchi M; Kaya M; Wada T; Baba I; Kudawara I; Aoki Y; Yoshikawa H
Oncol Rep; 2008 Feb; 19(2):467-76. PubMed ID: 18202796
[TBL] [Abstract][Full Text] [Related]
11. Expression of FGFR3 and FGFR4 and clinical risk factors associated with progression-free survival in synovial sarcoma.
Charbonneau B; Vogel RI; Manivel JC; Rizzardi A; Schmechel SC; Ognjanovic S; Subramanian S; Largaespada D; Weigel B
Hum Pathol; 2013 Sep; 44(9):1918-26. PubMed ID: 23664540
[TBL] [Abstract][Full Text] [Related]
12. Identification of syt-ssx fusion transcripts in both epithelial and spindle cell components of biphasic synovial sarcoma in small tissue samples isolated by membrane-based laser microdissection.
Nishio J; Iwasaki H; Ishiguro M; Ohjimi Y; Isayama T; Naito M; Kikuchi M
Virchows Arch; 2001 Aug; 439(2):152-7. PubMed ID: 11561755
[TBL] [Abstract][Full Text] [Related]
13. Dysadherin expression as a significant prognostic factor and as a determinant of histologic features in synovial sarcoma: special reference to its inverse relationship with E-cadherin expression.
Izumi T; Oda Y; Hasegawa T; Nakanishi Y; Kawai A; Sonobe H; Takahira T; Kobayashi C; Yamamoto H; Tamiya S; Hirohashi S; Iwamoto Y; Tsuneyoshi M
Am J Surg Pathol; 2007 Jan; 31(1):85-94. PubMed ID: 17197923
[TBL] [Abstract][Full Text] [Related]
14. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients.
Ladanyi M; Antonescu CR; Leung DH; Woodruff JM; Kawai A; Healey JH; Brennan MF; Bridge JA; Neff JR; Barr FG; Goldsmith JD; Brooks JS; Goldblum JR; Ali SZ; Shipley J; Cooper CS; Fisher C; Skytting B; Larsson O
Cancer Res; 2002 Jan; 62(1):135-40. PubMed ID: 11782370
[TBL] [Abstract][Full Text] [Related]
15. Synovial sarcoma: identification of low and high risk groups.
Bergh P; Meis-Kindblom JM; Gherlinzoni F; Berlin O; Bacchini P; Bertoni F; Gunterberg B; Kindblom LG
Cancer; 1999 Jun; 85(12):2596-607. PubMed ID: 10375108
[TBL] [Abstract][Full Text] [Related]
16. Truncated SSX protein suppresses synovial sarcoma cell proliferation by inhibiting the localization of SS18-SSX fusion protein.
Yoneda Y; Ito S; Kunisada T; Morimoto Y; Kanzaki H; Yoshida A; Shimizu K; Ozaki T; Ouchida M
PLoS One; 2013; 8(10):e77564. PubMed ID: 24130893
[TBL] [Abstract][Full Text] [Related]
17. Synovial sarcoma: a clinicopathologic, staging, and prognostic assessment.
Spillane AJ; A'Hern R; Judson IR; Fisher C; Thomas JM
J Clin Oncol; 2000 Nov; 18(22):3794-803. PubMed ID: 11078492
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors in synovial sarcoma: a clinicopathologic study of 18 cases.
Yokoyama K; Shinohara N; Kondo M; Mashima T
Jpn J Clin Oncol; 1995 Aug; 25(4):131-4. PubMed ID: 7666589
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic utility of dual-color break-apart chromogenic in situ hybridization for the detection of rearranged SS18 in formalin-fixed, paraffin-embedded synovial sarcoma.
Motoi T; Kumagai A; Tsuji K; Imamura T; Fukusato T
Hum Pathol; 2010 Oct; 41(10):1397-404. PubMed ID: 20594581
[TBL] [Abstract][Full Text] [Related]
20. The classic prognostic factors tumor stage, tumor size, and tumor grade are the strongest predictors of outcome in synovial sarcoma: no role for SSX fusion type or ezrin expression.
ten Heuvel SE; Hoekstra HJ; Bastiaannet E; Suurmeijer AJ
Appl Immunohistochem Mol Morphol; 2009 May; 17(3):189-95. PubMed ID: 18997619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
